The p53 tumor suppressor gene product is a transcriptional transacti vator and a potent apoptotic inducer. The fact that many of the DNA tumor virus oncoproteins bind to p53 and affect these p53 functions Indicates that this interaction is an important step in oncogenic transfor mation. We and others have recently demonstrated that the hepatitis B virus oncoprotein, HBx, can form a complex with p53 and inhibit its DNA consensus sequence binding and transcriptional transactivator activity.
Introduction
The p53 tumor suppressor gene product is involved in the mainte nance of genomic integrity (1). Various DNA tumor viruses encode transforming oncoproteins that interact with p53. These include T antigen from 5V40 (2, 3), E6 from oncogenic HPV3 (4), E1B Mr 55,000 protein from adenovirus (5), EBNA-5 from EBV (6), 1E84 from human CMV (7), and HBx from HBV (8) (9) (10) . Among them, T antigen from SV4O and E1B Mr 55,000 proteins have been shown to inhibit p53-dependent programmed cell death (apoptosis; Refs. 11 and 12) , an intrinsic cellular process essential for maintaining tissue ho meostasis (13, 14) . In addition, 1E84 was also shown to abolish p53 transcriptional activation, which may lead to coronary restenosis (7) . p53 is a potent inducer of apoptosis (15, 16) , which contributes to its function as a tumor suppressor gene (17â€"19).Disruption of p53-mediated apoptosis by viral oncoproteins may be an important step in carcinogenesis.
HBV is a major risk factor associated with hepatocarcinogenesis Received I0/5/95; accepted I 1/1/95. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. (10, 28) . The HBx gene is frequently integrated into the genorne (29) and expressed (30) in hepatocellular carcinoma from the geographic areas of high cancer incidence. Human hepatocellular carcinoma, which accounts for over 90% of primary liver cancers, can progress through inactivation of the p53 gene via mutations (31â€"33) and/or interaction with HBx (8â€"10).
We, and others, have recently shown that HBx can bind to p53 in vivo and in vitro (8â€"10);inhibit p53 sequence-specific DNA binding and transcriptional activation; prevent p53 binding to the transcription repair factor, XPB (9, 34) ; and prevent p53 entry into the nucleus (10) .
To further explore the oncogenic mechanism of HBx, including the hypothesis that HBx can block the induction of p53-mediated apop tosis, we examined the physical and functional interactions between p53 and HBx in the p53-mediated apoptotic pathway.
Materials and Methods
Cell Cultures and Microinjection. Cell strains, culture conditions, and microinjection were essentially as described (35 In Vitro Protein-binding Assay. Expressionand purificationof recombi nant proteins, as well as in vitro protein binding and analyses of protein complexes, have been described previously (9) . GST fusion proteins were produced in Escherichia coli and purified on glutathione-Sepharose 4B beads according to the manufacturer's instructions (Pharmacia LKB, Piscataway, NJ induced apoptosis of normal primary human fibroblasts was wt specific because p53 mutants (1435k@,175his 248t@, and 249S@) failed to induce apoptosis and, in fact, blocked wt-induced apop tosis, although the mutant protein levels were equal to or exceeding that obtained with wt p53. 4 We then coinjected wt p53 and HBx genes (both CMV promoter driven) into the nuclei of primary human fibroblasts. Elevated levels of p53 were observed 24 h after coinjection, comparable to the amount seen with wt alone, when both microinjections were performed on the same slide (Fig. 1D) , indicating that HBx did not influence the expression of exogenous p53 gene. However, the addition of HBx resulted in only 2% of the p53 immunopositive cells displaying the apoptotic phenotype (Table 1) , in contrast to the 19% seen with wt p53 alone. It was of interest that coinjection of HBx and p53 resulted in an increased percentage of cells with p53 accumulation in the nucleus-only cells (81%), as compared to 32% when p53 alone was microinjected.
Similar results were obtained in normal primary human fibroblasts from a different donor (GM07532; data not shown). Therefore, we conclude that HBx can efficiently block p53-mediated apoptosis in primary human fibroblasts.
We recently observed that p53-induced apoptosis involves the TFIIH-associated factors XPB and XPD (34)â€¢4 Therefore, we ex amined whether HBx may prevent p53-induced apoptosis by in hibiting binding of p53 to the XP proteins. Our approach involved an in vitro binding/competition assay between a GST-p53 fusion protein and in vitro translated XPB, XPD, or HBx proteins (Fig. 2) . Although HBx itself did not bind to XPB protein in vitro (data not shown), it prevented the binding of p53 to both XPB and XPD proteins (Fig. 2, A and B) . This inhibition was specific to XPB and XPD because HBx did not inhibit p53 binding to hRAD5 1 (data not shown), a human RecA-like protein that may be involved in 
Results and Discussion
Apoptosis was examined by using a microinjection technique to introduce CMV-driven p53 expression vector into the nucleus of normal human primary fibroblasts. Injection of the wt p.53 gene resulted in elevated p53 levels, accumulating predominantly in the nucleus (32%) or in both the nucleus and cytoplasm (68%; Fig. 1A and Table I ). No cytoplasm-only staining of p53 was observed (Table 1) . p53 was virtually undetectable by immunohistochemis try in uninjected cells (Fig. 1A) . Of the p53-immunopositive cells identified after a 24-h incubation, 19% exhibited the characteristic features of apoptosis (chromatin condensation, nuclear fragmenta tion, and apoptotic bodies; Fig. 1 , B and C, and Table 1 ). p53- involved in binding to XPB and XPD proteins, may be responsible for binding to hRad5l.6 This may explain why HBx did not inhibit p53 binding to hRad5i. It is likely that HBx protein prevents p53 binding to the XPB and XPD proteins by masking the p53 CTD.
We then examined whether HBx can block p53-mediated up regulation of target genes, such as @2JwAFIwhich was shown to be elevated during p53-mediated apoptosis (38) . Microinjection of the wt p53 expression vector into normal primary human fibroblasts resulted in increase of both p53 and p21wAFl protein levels. Sixty % of p53-irnmunopositive cells also exhibited expression of p21wAFI (Fig.  4) . Whereas the p53 protein was undetectable in uninjected cells, about 5% of these cells were immunopositive for p21WAF1 (Fig. 4) , indicating p53-independent p21wAFI expression. Coinjection of HBx and wt p53 into cells on the same slide that was injected in parallel with wt p53 alone resulted in a moderate decrease in @21wAFi immunopositive cells (about 40%; P < 0.05; Fig. 4 ). This suggests that HBx can reduce the expression of endogenous genes regulated by p53. This finding is consistent with our previous observation that HBx blocks pS3 transcriptional activation of the PG13CAT reporter con struct (9) . Failure of p53 to transactivate in the presence of HBx may be the result of p53-DNA interactions by HBx (9) . Therefore, HBx appears to abrogate two p53 functions, apoptosis and transcriptional transactivation, both of which may be important for its tumor sup pressor function (17â€"19).
HBx has a less pronounced effect on p53-mediated transactiva tion than on p53 binding to the XP proteins tested and p53-mediated apoptosis (compare Table 1 to Figs. 2 and 4) . Further more, microinjection of a CMV promoter-driven @ gene into normal human fibroblasts did not result in apoptosis (data not shown). Although these results do not rule out the possibility that HBx inhibits p53-induced apoptosis by abrogating transactivation 3 0 of other p53-regulated genes other than @2JwAF1 such as GADD45, Bax, and Fas (39â€"41), our data are consistent with recent findings that p53-mediated apoptosis does not require acti vation of downstream genes (42, 43),4 and that p53-mediated transactivation is not required for its tumor suppressor function (44) . Thus, we favor the model that HBx blocks p53-mediated apoptosis by disrupting its binding to the XPB/XPD complex, which may be important in p53-dependent apoptosis.
A recent report (45) indicated that the p53-mediated cellular re sponse to DNA damage is normal in a hepatoblastoma cell line (HepG2) genetically engineered to produce replicative hepatitis B virus. Because HBx is likely to be expressed during HBV replication, the authors suggested that p53 may not be inactivated at the â€oephysi ological conditionsâ€• of their experiments. The explanation for the apparent discrepancy between this report and other recent data is not clear at the present time. One possibility could be the level of HBx expression at different conditions. In fact, HBV-related hepatocellular carcinoma cells do not have replicating form of the virus and instead have integrated DNA sequences including HBx (30, 46) , which prob ably express a subset and different level of viral proteins when compared to the intact virus.
p53-mediated apoptosis is an important factor in maintaining tissue homeostasis and preventing neoplastic transformation (17â€" 19). Inactivation of p53-mediated apoptosis by HBx could lead to the disruption of the normal cellular surveillance mechanism for removing damaged cells, which could result in the accumulation of genetically abnormal cells, from which clones with a survival advantage would be selected. Thus, reduction of p53-mediated apoptosis by HBx may contribute to the development of human hepatocellular carcinoma. DNA recombination (36) . hRAD51 was recently shown to specif ically associate with p53 in vitro.5 '6 Since the COOH-terminal domain of p53 (between residues 293 and 393) is responsible for the interaction with XPB and XPD (34), we mapped the region of p53 required for binding to HBx. Mutant p53 proteins with deletions at the COOH terminus (residues 293â€"393) completely lost the ability to bind to HBx, whereas p53 mutants with deletions at the NH2 terminus (residues 1â€"94) retained this ability (Fig. 3) . Further deletion of up to 154 N-terminal residues containing part of the DNA binding domain exhibited reduced binding to HBx. These mapping data indicate that the C-terminal domain (CTh) of PS3, which is required for binding to the XP proteins, is also involved in the interaction with HBx. However, the N-terminal domain of p53 (1â€"94), a region possessing the transactivation domain and targeted by the viral oncoproteins E1B and E6 (4, 5, 37) , does not interact with HBx. Additional data showed that p53 domains, other than the CTh terminus of p53: N5, deletion of 100 residues at the COOH terminus of p53; 2C, deletion of 94 residues at the NH2 terminus of pS3; 3C, deletion of 155 residues at the NH2 terminus of p53: 25, deletion of 94 residues at the NH2 terminus and 100 residues at the COOH terminus. Columns, average of three mdc pendent experiments; bars, SD. The p53 protein was normally undetectable in uninjected cells, and the @21wAFI protein was occasionally detected in uninjected cells; these were expressed as the background @21w@.vt staining (0). A Student's t test was used to compare wt p53 plus HBx group to the wt p53 alone group, and a P value < 0.05 was obtained.
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